ALFA Finder| Management target | Revenue FY30 |
|---|
| Revenue growth | Q2 +108% YoY; H1 +140% YoY |
|---|---|
| Margins | Q2 EBITDA margin 9.9% vs 10.7% YoY; PAT margin 3.5% |
| Demand visibility | Strong domestic and export demand cited by management |
Growth
Q2 revenue ₹508.9 Cr vs ₹244.6 Cr (+108% YoY). H1 revenue ₹998.5 Cr vs ₹415.4 Cr (+140%). Q2 PAT ₹17.7 Cr vs ₹6.9 Cr.
Outlook
FY30 revenue target ₹3,000+ Cr versus ₹1,449 Cr in FY26. Oman Al Juba capacity and backward integration into fishing assets.
Risks
EBITDA margin fell to 9.9% from 10.7% YoY. Deck flags fishmeal supply shortfall from 2028 and climate disruption.
Investor Presentation filed with BSE, NSE: MUKKA. Summary written with AI assistance from the document.
Mukka Proteins Ltd: key numbers
- Share price
- ₹27.17
- Market cap
- ₹815.1 Cr
- Revenue (annual)
- ₹1,449 Cr
- Net profit (annual)
- ₹52.06 Cr
- P/E (TTM)
- 10.3×Sector 29.0×
- Promoter holding
- 73.33%+0.00% QoQ
- FII holding
- 1.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mukka Proteins Ltd
All →Mukka Proteins Results Update
Mukka Proteins reported Q2 FY27 revenue up 108% YoY to Rs.5,088.70 Mn. The Oman facility began commercial production, adding 37,200 MTPA of capacity.
- Oman facility manufacturing capacity
- 37200.0 MTPA
Mukka Proteins Acquisition Worth ₹2.13 Cr
Mukka Proteins' board approved revised terms to acquire 85,200 equity shares, a 46% stake, in Swachha Eco Solutions for up to Rs 2.13 Crore. The unlisted waste-management company is not a related party.
- Value
- ₹2.13 Cr
- Execution
- Up to 31-03-2027
Mukka Proteins Other Announcement
Mukka Proteins filed its quarterly statement of deviation for funds raised through a preferential warrant issue, reporting no deviation. Utilisation of Rs. 11.75 Crore against the working capital object is shown for the quarter ended September 2026.
Mukka Proteins Q2 FY27 Results: Net Profit ₹17.7 Cr, Up 156.5% YoY
Mukka Proteins Ltd reported revenue from operations of ₹508.9 Cr (+108.1% YoY) and net profit of ₹17.7 Cr (+156.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹17.7 Cr · +156.5% YoY
Mukka Proteins Board Meeting Date
Mukka Proteins intimated a board meeting on 07 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closure is also disclosed.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027